Telix Appoints Former Pfizer CMO and Ex-Stryker CFO to Board
Telix Pharmaceuticals on May 11, 2026 adds Non-Executive Directors Maria Rivas, MD—a former Pfizer CMO and Cooper Companies board member—and finance veteran Bill Jellison, ex-Stryker CFO and Medtronic director. Their governance, clinical development and financial oversight experience bolsters Telix’s evolution as a dual-listed commercial biopharmaceutical.
1. Strategic Board Expansion
Telix Pharmaceuticals announced appointments of Maria Rivas and William Jellison as Non-Executive Directors effective May 11, 2026, expanding its board from succession planning and to enhance strategic oversight following the recent addition of David Gill.
2. Maria Rivas Brings Clinical Leadership
Dr. Maria Rivas offers over 25 years of late-stage clinical development and commercial expertise, having served as Pfizer Chief Medical Officer, a director at Cooper Companies, and an independent board member at Medidata, with a track record in oncology, rare diseases and neurosciences.
3. Bill Jellison Adds Financial Oversight
William Jellison contributes more than 30 years of corporate finance leadership, including his tenure as Stryker CFO overseeing SEC reporting, M&A and capital allocation, along with board roles at Medtronic, Anika Therapeutics and other regulated enterprises.
4. Strengthening Governance for Commercial Growth
The combined expertise in governance, clinical development and financial management aligns with Telix’s goals as a dual-listed, commercial-stage biopharmaceutical company focused on radiopharmaceutical development and global market expansion.